- Home
- VRPX
as 10-04-2024 4:00pm EST
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BERWYN |
| Market Cap: | 3.3M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 52.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $9.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Virpax Pharmaceuticals Inc. News
VRPX Breaking Stock News: Dive into VRPX Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
Business Wire
2 months ago
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
Business Wire
2 months ago
Virpax Regains Compliance with Nasdaq Minimum Bid Price
Benzinga
3 months ago
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
MT Newswires
3 months ago
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Business Wire
3 months ago
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
Business Wire
3 months ago
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
Business Wire
4 months ago
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
Compare VRPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRPX Virpax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.